Department of Molecular Microbiology, John Innes Centre, Norwich, United Kingdom.
School of Biological Sciences, University of East Anglia, Norwich, United Kingdom.
Appl Environ Microbiol. 2020 Jan 21;86(3). doi: 10.1128/AEM.01876-19.
Most clinical antibiotics are derived from actinomycete natural products discovered at least 60 years ago. However, the repeated rediscovery of known compounds led the pharmaceutical industry to largely discard microbial natural products (NPs) as a source of new chemical diversity. Recent advances in genome sequencing have revealed that these organisms have the potential to make many more NPs than previously thought. Approaches to unlock NP biosynthesis by genetic manipulation of strains, by the application of chemical genetics, or by microbial cocultivation have resulted in the identification of new antibacterial compounds. Concomitantly, intensive exploration of coevolved ecological niches, such as insect-microbe defensive symbioses, has revealed these to be a rich source of chemical novelty. Here, we report the new lanthipeptide antibiotic kyamicin, which was generated through the activation of a cryptic biosynthetic gene cluster identified by genome mining species found in the obligate domatium-dwelling ant of the ant plant Transcriptional activation of this silent gene cluster was achieved by ectopic expression of a pathway-specific activator under the control of a constitutive promoter. Subsequently, a heterologous production platform was developed which enabled the purification of kyamicin for structural characterization and bioactivity determination. This strategy was also successful for the production of lantibiotics from other genera, paving the way for a synthetic heterologous expression platform for the discovery of lanthipeptides that are not detected under laboratory conditions or that are new to nature. The discovery of novel antibiotics to tackle the growing threat of antimicrobial resistance is impeded by difficulties in accessing the full biosynthetic potential of microorganisms. The development of new tools to unlock the biosynthesis of cryptic bacterial natural products will greatly increase the repertoire of natural product scaffolds. Here, we report a strategy for the ectopic expression of pathway-specific positive regulators that can be rapidly applied to activate the biosynthesis of cryptic lanthipeptide biosynthetic gene clusters. This allowed the discovery of a new lanthipeptide antibiotic directly from the native host and via heterologous expression.
大多数临床抗生素都来源于放线菌天然产物,这些天然产物是至少 60 年前发现的。然而,由于已知化合物的反复重新发现,制药行业在很大程度上放弃了微生物天然产物 (NPs) 作为新化学多样性的来源。最近基因组测序的进展表明,这些生物体有可能产生比以前想象的更多的 NPs。通过遗传操纵菌株、应用化学遗传学或微生物共培养来解锁 NP 生物合成的方法,已经鉴定出了新的抗菌化合物。同时,对共同进化的生态位(如昆虫-微生物防御共生关系)的深入探索表明,这些是化学新颖性的丰富来源。在这里,我们报告了新的 lanthipeptide 抗生素 kyamicin,它是通过对在专性 domatium 居住的蚂蚁物种 中发现的基因簇进行基因组挖掘而产生的。通过在组成型启动子的控制下异位表达途径特异性激活剂,激活了这个沉默的基因簇。随后,开发了一个异源生产平台,该平台能够纯化 kyamicin 进行结构表征和生物活性测定。这种策略也成功地用于从其他属生产 lantibiotics,为发现不在实验室条件下检测到或自然界中新的 lanthipeptides 的合成异源表达平台铺平了道路。由于难以获得微生物的全部生物合成潜力,新型抗生素的开发以应对日益严重的抗菌药物耐药性威胁受到阻碍。开发新的工具来解锁隐藏的细菌天然产物的生物合成将极大地增加天然产物支架的种类。在这里,我们报告了一种用于异位表达途径特异性正调控因子的策略,该策略可以快速应用于激活隐藏的 lanthipeptide 生物合成基因簇的生物合成。这使得可以直接从天然宿主和异源表达中发现新的 lanthipeptide 抗生素。